secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2026-08-10T11:13:38+00:00
Accession:  0001193125-26-341229
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jade Biosciences Q2 2026 net loss $55.8M; JADE101 Phase 1 data positive, cash $461M
--------------------------------------------------------------------------------

- Q2 2026 net loss $55.8M vs $32.1M in Q2 2025; R&D $50.1M, G&A $8.9M.
- Cash, equivalents, investments $461.2M as of June 30, 2026; runway into Q4 2028 after $172.5M offering.
- JADE101 Phase 1: ~70% mean IgA reduction after single 700mg dose; supports every-12-week dosing; Phase 2 JUNIPER underway, Phase 3 expected H1 2027.
- JADE201 Phase 1 in rheumatoid arthritis dosing began; interim data 2027. JADE301 for dermatomyositis unveiled; Phase 1 healthy volunteers expected Q4 2026.
- Mark Eisner, M.D., appointed to board; company advancing pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/0001193125-26-341229-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526341229/d40629d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-341229

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer